CClinicalTrials.gg
Status unknownNCT03400280PORSCHUpdated Jun 14, 2019

POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection

An interventional study of Best practice algorithm for postoperative care in Pancreatic Diseases, Pancreatic Neoplasms and Pancreatic Cancer, sponsored by St. Antonius Hospital. Status unknown at 17 sites in Netherlands. Per ClinicalTrials.gov, last updated 2019-06-14.

Sponsored by St. Antonius Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Sex
All
01

Study summary

This Nationwide stepped-wedge cluster randomized trial is designed to evaluate if the implementation of a best practice algorithm for postoperative care results in a decrease in incidence of major complications and death after pancreatic resection as compared to current practice.

Read the detailed description

Rationale

Pancreatic resection is a major abdominal operation with 50% chance of postoperative complications. A feared complication is severe pancreatic fistula, in which there is leakage of enzyme rich fluid into the abdominal cavity. Adequate complication management appears to be the most important factor in improving outcomes of patients undergoing pancreatic resection.

Objective

To investigate whether implementation of a best practice algorithm for postoperative care focusing on early detection and step-up management of postoperative pancreatic fistula results in a lower rate of major complications and death after pancreatic resection as compared to current practice

Study design

A nationwide stepped-wedge, cluster randomized, superiority trial. In this design all participating centers cross over from current practice to best practice according to the algorithm, but are randomized to determine the exact order. At the end of the trial, all centers will have implemented the best practice algorithm.

Study population

All centers performing pancreatic surgery in the Netherlands (i.e. the Dutch Pancreatic Cancer Group).

Intervention

Cluster level education on postoperative care according to a best practice algorithm, focusing on early detection and step-up management of postoperative pancreatic fistula. This algorithm is based on findings in Dutch observational cohort studies, systematic literature analyses, an inventory in current protocols on postoperative care and expert opinion. The proposed algorithm is validated in a multicenter cohort and consensus upon this algorithm is reached with pancreatic surgeons from all centers of the Dutch Pancreatic Cancer Group. The final algorithm was reviewed critically by the advisory committee of internationally respected experts in the field of pancreatology before implementation in this trial.

Comparison

Postoperative care according to current practice.

Endpoints

The primary outcome was measured in all patients undergoing pancreatic resection and is a composite of major complications (i.e. postpancreatectomy bleeding, new-onset organ failure and death). Secondary endpoints include the individual components of the primary endpoint and other clinical outcomes, number of patients receiving adjuvant chemotherapy, healthcare resource utilization and costs analysis. Follow-up will be 90 days after pancreatic resection.

02

Conditions studied

  • Pancreatic Diseases
  • Pancreatic Neoplasms
  • Pancreatic Cancer
  • Pancreatitis

Keywords

  • Postoperative pancreatic fistula
  • Pancreatic resection
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Clusters:

  • All Dutch centers performing pancreatic surgery (i.e. performing at least 20 pancreatoduodenectomies a year)

Exclusion Criteria for Clusters:

  • None

Inclusion Criteria for Patients:

  • Patients underoging pancreatic resection for any indication

Exclusion Criteria for Patients:

  • None (i.e. complete enumeration)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
1,600 participants (estimated)

Study arms

  • Experimental
    Best practice

    Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.

    Other: Best practice algorithm for postoperative care

  • No intervention
    Current practice

    Postoperative care according to current usual practice.

Interventions

  • OtherBest practice algorithm for postoperative care

    See arm/group description

05

What researchers measure

Primary outcomes

  1. Composite primary endpoint

    The primary endpoint of this trial is a composite of the most severe complications associated to postoperative pancreatic fistula. This endpoint will be considered positive if one of the following complications occurs within 90 days after pancreatic resection: late postpancreatectomy bleeding, new-onset organ failure and/or death

    Time frame: 90 days after index pancreatic resection

Secondary outcomes

  1. Postoperative mortality

    Measured as rate of death at 90-day follow-up

    Time frame: 90 days after index pancreatic resection

  2. New-onset organ failure

    Measured as organ failure occuring any time within 90 days after resection, not present at time of index pancreatic resection.

    Time frame: 90 days after index pancreatic resection

  3. Late postpancreatectomy bleeding

    Defined in accordance to the International Study Group on Pancreatic Surgery (ISGPS) definition as bleeding occurring any time after 24 hours after pancreatic resection.

    Time frame: 90 days after index pancreatic resection

  4. Postoperative morbidity

    Including complications according to the Clavien-Dindo system and pancreatectomy specific complications according to the ISGPS definitions (e.g. postpancreatectomy bleeding, postoperative pancreatic fistula, postoperative bile leak, postoperative chyle leak and delayed gastric emptying).

    Time frame: 90 days after index pancreatic resection

  5. Adjuvant chemotherapy

    Measured as number of patients receiving adjuvant chemotherapy at 90-day follow-up

    Time frame: 90 days after index pancreatic resection

  6. Success of implementation

    Measured as number of patients in whom the algorithm was not followed and timing of abdominal CT scans in both strategies.

    Time frame: 90 days after index pancreatic resection

  7. Cost-effectiveness

    Calculated by comparing health effects and medical costs related to both strategies up to 90 days after pancreatic resection.

    Time frame: 90 days after index pancreatic resection

06

Study locations

17 of 17 sites recruiting
  • Jeroen Bosch Ziekenhuis
    's Hertogenbosch, Netherlands
    • Koop Bosscha · Contact
    Recruiting
  • Academic Medical Center
    Amsterdam, Netherlands
    • Marc Besselink · Contact
    Recruiting
  • Onze Lieve Vrouwen Gasthuis
    Amsterdam, Netherlands
    • Sebastiaan Festen · Contact
    Recruiting
  • VUmc
    Amsterdam, Netherlands
    • Geert Kazemier · Contact
    Recruiting
  • Amphia ziekenhuis
    Breda, Netherlands
    • Jennifer Schreinemakers · Contact
    Recruiting
  • Reinier de Graaf gasthuis
    Delft, Netherlands
    • Daphne Roos · Contact
    Recruiting
  • Catharina ziekenhuis
    Eindhoven, Netherlands
    • Ignace de Hingh · Contact
    Recruiting
  • Medisch Spectrum Twente
    Enschede, Netherlands
    • Mike Liem · Contact
    Recruiting
  • UMCG
    Groningen, Netherlands
    • Vincent de Meijer · Contact
    Recruiting
  • Tjongerschans
    Heerenveen, Netherlands
    • Fennie Wit · Contact
    Recruiting
  • LUMC
    Leiden, Netherlands
    • Bert Bonsing · Contact
    Recruiting
  • Maastricht UMC
    Maastricht, Netherlands
    • Ronald van Dam · Contact
    Recruiting
  • Radboud UMC
    Nijmegen, Netherlands
    • Marion van der Kolk · Contact
    Recruiting
  • Erasmus MC
    Rotterdam, Netherlands
    • Casper van Eijck · Contact
    Recruiting
  • Maasstad ziekenhuis
    Rotterdam, Netherlands
    • Erwin van der Harst · Contact
    Recruiting
  • RAKU (St. Antonius ziekenhuis & UMC Utrecht)
    Utrecht, Netherlands
    • Hjalmar van Santvoort · Contact
    • Quintus Molenaar · Contact
    Recruiting
  • Isala klinieken
    Zwolle, Netherlands
    • Gijs Patijn · Contact
    Recruiting
07

References and documents

Publications

  • Smits FJ, Molenaar IQ, Besselink MG, Busch OR, van Eijck CH, van Santvoort HC; Dutch Pancreatic Cancer Group. Management of postoperative pancreatic fistula after pancreatoduodenectomy: high mortality after completion pancreatectomy: Reply to: Bressan et al. completion pancreatectomy in the acute management of pancreatic fistula after pancreaticoduodenectomy. HPB (Oxford). 2018 Dec;20(12):1223. doi: 10.1016/j.hpb.2018.05.015. Epub 2018 Jun 22. No abstract available. PubMed 29941289 ↗

Individual participant data

Plan to share: Yes — The datasets generated during and/or analysed during the current study are/will be available upon request from Hjalmar van Santvoort (h.van.santvoort@antoniusziekenhuis.nl)

Supporting information: Study protocol

08

Registry details

Key details

Study ID
NCT03400280
Lead sponsor
St. Antonius Hospital
Collaborators
Dutch Cancer Society
Responsible party
HC van Santvoort (Principal Investigator, St. Antonius Hospital) — Principal investigator
First posted
Jan 17, 2018
Start date
Jan 8, 2018
Primary completion
Nov 9, 2019 (estimated)
Completion
Feb 9, 2020 (estimated)
Last update
Jun 14, 2019

Study contacts

Jasmijn Smits, MD
Contact
porsch@dpcg.nl
+31887571207
Hjalmar C van Santvoort, MD, PhD
Contact
h.vansantvoort@umcutrecht.nl
+31887556489
Quintus Molenaar, MD, PhD
principal investigator · UMC Utrecht
Hjalmar C van Santvoort, MD, PhD
principal investigator · St. Antonius Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion